Gilead strikes deal to make remdesivir coronavirus treatment in 127 countries

- Advertisement -
KEY POINTS
  • Gilead Sciences has struck a licensing agreement with five generic drugmakers to make antiviral drug remdesivir in 127 countries, not including the United States.
  • The deal is “royalty-free” until WHO says the Covid-19 outbreak is no longer a global health crisis or “until a pharmaceutical product other than remdesivir or a vaccine is approved to treat or prevent Covid-19.”
- Advertisement -
- Advertisement -
- Advertisement -
A lab technician visually inspects a filled vial of investigational coronavirus disease (COVID-19) treatment drug remdesivir at a Gilead Sciences facility
A lab technician visually inspects a filled vial of investigational coronavirus disease (COVID-19) treatment drug remdesivir at a Gilead Sciences facility in La Verne, California, March 11, 2020.
Gilead Sciences | via REUTERS

Gilead Sciences has struck a licensing agreement with five generic drugmakers to make antiviral drug remdesivir in 127 countries, not including the United States, the company announced Tuesday.

Drugmakers Mylan, Cipla, Ferozsons Laboratories, Hetero Labs and Jubilant Lifesciences will manufacture remdesivir for distribution in “low-income and lower-middle-income countries, as well as several upper-middle- and high-income countries” that face health-care obstacles amid the coronavirus pandemic, the company said.

The deal is “royalty-free” until the World Health Organization says the Covid-19 outbreak is no longer a global health crisis or “until a pharmaceutical product other than remdesivir or a vaccine is approved to treat or prevent Covid-19, whichever is earlier,” the company said.

The Food and Drug Administration on May 1 granted emergency use authorization for Gilead’s remdesivir drug to treat Covid-19, which has infected more than 4 million people across the globe in a little over four months, according to data compiled by Johns Hopkins University.

The intravenous drug has helped shorten the recovery time of some hospitalized Covid-19 patients, new clinical trial data suggests. Without other proven treatments, physicians will likely be considering its use to treat the coronavirus.

Gilead CEO Daniel O’Day told CNBC earlier this month that the company was working to expand its supply chain after learning from other serious outbreaks such as influenza.

The company has said it expects to produce more than 140,000 rounds of its 10-day treatment regimen by the end of this month and anticipates it can make 1 million rounds by the end of this year. Gilead said it will be able to produce “several million” rounds of its antiviral drug next year.

Home of Science
Follow me

- Advertisement -

Discover

Sponsor

Latest

Discover the Benefits of Amazon Prime

If you have yet to discover the benefits of becoming a member of Amazon Prime, then this is the perfect time for you to...

Elon Musk ends $44bn bid to buy Twitteron July 8, 2022 at 9:42 pm

Elon Musk says he is ending $44bn (£36.2bn) bid to buy Twitter, alleging multiple breaches of agreement.Elon Musk says he is ending $44bn (£36.2bn)...

Test and Trace boss Dido Harding to step down from NHS roleon August 9, 2021 at 4:29 pm

Boris Johnson promised a "world-beating" system, but it was heavily criticised during her tenure.Baroness Dido Harding, who ran the government's Covid-19 test-and-trace programme in...

Publish Sue Gray’s No 10 parties report in full, Starmer urges PMon January 26, 2022 at 1:46 pm

The Labour leader tells Boris Johnson to quit during a bad-tempered series of Commons exchanges.This video can not be playedTo play this video you...

Prince William turns 40: Birthday photos show duke’s prioritieson June 20, 2022 at 9:45 pm

As he turns 40, the duke conveys his focus on issues like homelessness and the environment.As he turns 40, the duke conveys his focus...
Home of Science
Follow me